Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Asset Resilience Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. asset resilience ratio. Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has an Asset Resilience Ratio of 1.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Hangzhou Bio-Sincerity Pharma-Tech Co.Lt fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2024–2025)
Asset resilience ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2024 to 2025. This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Asset Resilience Ratio has changed over time. Read 301096 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥60.00 Million | 1.58% |
| Total Liquid Assets | CN¥60.00 Million | 1.58% |
Asset Resilience Insights
- Limited Liquidity: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. maintains only 1.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Industry Peers by Asset Resilience Ratio
Compare Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
Novo Nordisk A/S
CO:NOVO-B |
Drug Manufacturers - General | 0.09% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR |
Drug Manufacturers - General | 0.07% |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Asset Resilience Ratio by Year (2024–2025)
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.17% | CN¥80.00 Million ≈ $11.71 Million |
CN¥3.69 Billion ≈ $539.42 Million |
-0.06pp |
| 2024-12-31 | 2.23% | CN¥83.00 Million ≈ $12.15 Million |
CN¥3.72 Billion ≈ $544.53 Million |
-- |
About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more